Which has preferable earnings & valuation, MPLT or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is MPLT or RCKT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media refer more to MPLT or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Rocket Pharmaceuticals' score of 0.37 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, COAG or RCKT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is COAG or RCKT more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media prefer COAG or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.93 beat Rocket Pharmaceuticals' score of 0.37 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RCKT or CALT?

Rocket Pharmaceuticals presently has a consensus target price of $8.44, suggesting a potential upside of 207.07%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 3 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.38 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor WVE or RCKT?

In the previous week, WAVE Life Sciences had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for WAVE Life Sciences and 3 mentions for Rocket Pharmaceuticals. WAVE Life Sciences' average media sentiment score of 0.88 beat Rocket Pharmaceuticals' score of 0.37 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 1 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor COLL or RCKT?

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.93 beat Rocket Pharmaceuticals' score of 0.37 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rocket Pharmaceuticals (RCKT) Competitors

$2.75 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.73 -0.02 (-0.62%)

As of 06/12/2026 07:54 PM Eastern

Compare

RCKT vs. MPLT, COAG, CALT, WVE, and COLL

Should you buy Rocket Pharmaceuticals stock or one of its competitors? MarketBeat compares Rocket Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket Pharmaceuticals include Maplight Therapeutics (MPLT), Hemab Therapeutics (COAG), Calliditas Therapeutics AB (publ) (CALT), WAVE Life Sciences (WVE), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does Rocket Pharmaceuticals compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Maplight Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Rocket Pharmaceuticals' score of 0.37 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics presently has a consensus price target of $37.78, suggesting a potential upside of 36.14%. Rocket Pharmaceuticals has a consensus price target of $8.44, suggesting a potential upside of 207.07%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

Maplight Therapeutics beats Rocket Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Hemab Therapeutics currently has a consensus price target of $41.75, indicating a potential upside of 67.13%. Rocket Pharmaceuticals has a consensus price target of $8.44, indicating a potential upside of 207.07%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.93 beat Rocket Pharmaceuticals' score of 0.37 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Hemab Therapeutics' return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Summary

Rocket Pharmaceuticals beats Hemab Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Rocket Pharmaceuticals' return on equity of -69.61% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Rocket Pharmaceuticals' average media sentiment score of 0.37 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rocket Pharmaceuticals	Neutral
Calliditas Therapeutics AB (publ)	Neutral

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Rocket Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Rocket Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Rocket Pharmaceuticals presently has a consensus target price of $8.44, suggesting a potential upside of 207.07%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rocket Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Rocket Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

WAVE Life Sciences has higher revenue and earnings than Rocket Pharmaceuticals. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	26.43	-$204.38M	-$1.06	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Rocket Pharmaceuticals has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

WAVE Life Sciences presently has a consensus target price of $26.41, indicating a potential upside of 349.94%. Rocket Pharmaceuticals has a consensus target price of $8.44, indicating a potential upside of 207.07%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe WAVE Life Sciences is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, WAVE Life Sciences had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for WAVE Life Sciences and 3 mentions for Rocket Pharmaceuticals. WAVE Life Sciences' average media sentiment score of 0.88 beat Rocket Pharmaceuticals' score of 0.37 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	1 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

WAVE Life Sciences has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Summary

WAVE Life Sciences beats Rocket Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical currently has a consensus price target of $57.50, indicating a potential upside of 65.99%. Rocket Pharmaceuticals has a consensus price target of $8.44, indicating a potential upside of 207.07%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Collegium Pharmaceutical has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.44	$62.87M	$2.04	16.98
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to Rocket Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.93 beat Rocket Pharmaceuticals' score of 0.37 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Collegium Pharmaceutical beats Rocket Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$300.27M	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-1.47	20.00	23.99	24.42
Price / Sales	N/A	306.82	513.41	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.07	8.32	10.73	6.82
Net Income	-$223.12M	$23.94M	$3.57B	$337.56M
7 Day Performance	1.85%	1.84%	0.59%	1.17%
1 Month Performance	-15.38%	-0.04%	1.54%	3.16%
1 Year Performance	-6.14%	44.82%	25.42%	30.58%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.3844 of 5 stars	$2.75 flat	$8.44 +207.1%	-6.1%	$300.27M	N/A	N/A	240	Gap Down
MPLT Maplight Therapeutics	3.5019 of 5 stars	$29.46 +5.2%	$37.78 +28.2%	N/A	$1.19B	N/A	N/A	109
COAG Hemab Therapeutics	4.5776 of 5 stars	$25.55 +1.0%	$41.75 +63.4%	N/A	$1.19B	N/A	N/A	72	Quiet Period Expiration Gap Up
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
WVE WAVE Life Sciences	3.1017 of 5 stars	$5.70 -0.5%	$27.25 +378.1%	-15.5%	$1.10B	$42.73M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MPLT, COAG, CALT, WVE, and COLL

How does Rocket Pharmaceuticals compare to Maplight Therapeutics?

Summary

How does Rocket Pharmaceuticals compare to Hemab Therapeutics?

Summary

How does Rocket Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Summary

How does Rocket Pharmaceuticals compare to WAVE Life Sciences?

Summary

How does Rocket Pharmaceuticals compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MPLT, COAG, CALT, WVE, and COLL

How does Rocket Pharmaceuticals compare to Maplight Therapeutics?

Is MPLT or RCKT more profitable?

Which has preferable earnings & valuation, MPLT or RCKT?

Do institutionals and insiders hold more shares of MPLT or RCKT?

Does the media refer more to MPLT or RCKT?

Do analysts recommend MPLT or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Hemab Therapeutics?

Do analysts prefer COAG or RCKT?

Does the media prefer COAG or RCKT?

Do institutionals & insiders have more ownership in COAG or RCKT?

Is COAG or RCKT more profitable?

Which has better valuation and earnings, COAG or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Calliditas Therapeutics AB (publ)?

Is RCKT or CALT more profitable?

Does the media refer more to RCKT or CALT?

Do institutionals and insiders believe in RCKT or CALT?

Which has preferable earnings and valuation, RCKT or CALT?

Which has more volatility and risk, RCKT or CALT?

Do analysts rate RCKT or CALT?

Summary

How does Rocket Pharmaceuticals compare to WAVE Life Sciences?

Which has better valuation and earnings, WVE or RCKT?

Is WVE or RCKT more profitable?

Do analysts recommend WVE or RCKT?

Do institutionals and insiders believe in WVE or RCKT?

Does the media favor WVE or RCKT?

Which has more risk and volatility, WVE or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Collegium Pharmaceutical?

Do insiders and institutionals believe in COLL or RCKT?

Do analysts recommend COLL or RCKT?

Which has more risk & volatility, COLL or RCKT?

Which has higher earnings & valuation, COLL or RCKT?

Is COLL or RCKT more profitable?

Does the media favor COLL or RCKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools